Morgan Stanley analyst Terence Flynn has maintained their neutral stance on PRME stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Hold rating due to a combination of factors surrounding Prime Medicine, Inc. The company has successfully demonstrated clinical proof-of-concept for its prime editing platform, which is a positive development. However, the limited sample size of the study and the decision not to advance the CGD program internally indicate a cautious approach.
Moreover, Prime Medicine’s strategic restructuring to focus on in vivo programs, which are anticipated to have greater commercial potential, is a significant shift. Despite these promising steps, the next major clinical data from the in vivo liver franchise is not expected until 2027, which introduces a period of uncertainty. The extension of the company’s cash runway into the first half of 2026 provides some financial stability, but the lack of near-term catalysts justifies a Hold rating.